PALO ALTO, Calif., Jan. 4 /PRNewswire/ -- Corgentech, Inc., a
privately-held biotechnology company, today announced that John P. McLaughlin,
the company's president and chief executive officer, will present at the
JP Morgan H&Q 20th Annual Healthcare Conference on Tuesday, January 8. His
presentation will take place at 11:30 a.m. (PT) in the Oak Room at the Westin
St. Francis Hotel in San Francisco.
Corgentech, Inc. is committed to the discovery, development and
commercialization of novel molecular- and genetic-based therapies for the
treatment of cardiovascular and other serious diseases. The Company's lead
product, E2F Decoy, is designed to prevent vein grafts used in coronary artery
and peripheral arterial bypass procedures from blocking and failing and is in
the advanced stages of clinical development. Leveraging its leadership in
pressure-mediated transfection of decoy oligonucleotides to regulate
transactivation of genes, Corgentech's research engine is focused on other
promising therapeutic targets to provide treatments for other serious unmet
medical needs. For more information on the company and its technology, visit
http://www.corgentech.com.
SOURCE Corgentech, Inc.
 back to top
Related links:
http://www.corgentech.com
CONTACT:
Richard Powers of Corgentech,
+1-650-624-9600, or powers@corgentech.com; or Karen Halsey of
WeissCom Partners, +1-415-435-6342, or karen.halsey@attbi.com,
for Corgentech
|
